French trial opens in diabetes-diet drug scandal

May 14, 2012
Jacques Servier, center, founder of Servier Laboratories, sits with his lawyers during the opening of the trial at Nanterre's court house, outside Paris, Monday, May 14, 2012. A French court has opened the first of trials over a drug for diabetes commonly used to lose weight and suspected of killing at least 500 people. The pharmaceutical group Servier is suspected of "aggravated deception" for hiding the fact that the drug known as Mediator contained an amphetamine, benfluorex _ removed from the market in 2009 after being found to thicken heart valves. (AP Photo/Michel Euler)

(AP) -- The first French trial has begun over a diabetes drug that was also used to lose weight and is suspected in the deaths of at least 500 people.

The pharmaceutical group Servier is suspected of "aggravated deception" for hiding the fact that the drug known as Mediator contained an amphetamine called - which was taken off the market in 2009 after being found to thicken .

However, another investigation is underway and lawyers for Servier were arguing Monday against holding the current trial claiming that the laboratory could be judged twice on the same grounds.

The nature of benfluorex was allegedly hidden to obtain approval for the drug, first marketed in 1976. So far, charges have been filed against seven people, including drugmaker chief Jacques Servier.

Explore further: 'Fen-phen' derived drug responsible for thousands of hospitalizations and deaths in France

shares

Related Stories

'Fen-phen' derived drug responsible for thousands of hospitalizations and deaths in France

February 9, 2012
A new study published in the journal Pharmacoepidemiology & Drug Safety reveals that benfluorex, a fenfluramine derivative drug used in France under the name Mediator, is likely responsible for thousands of hospitalizations ...

FDA approves first generic versions of Zyprexa

October 24, 2011
(AP) -- Federal health officials on Monday approved the first generic versions of the blockbuster drug Zyprexa, an expensive treatment for schizophrenia and bipolar mood disorder.

Recommended for you

Study suggests ending opioid epidemic will take years

July 20, 2017
The question of how to stem the nation's opioid epidemic now has a major detailed response. A new study chaired by University of Virginia School of Law Professor Richard Bonnie provides extensive recommendations for curbing ...

Team-based model reduces prescription opioid use among patients with chronic pain by 40 percent

July 17, 2017
A new, team-based, primary care model is decreasing prescription opioid use among patients with chronic pain by 40 percent, according to a new study out of Boston Medical Center's Grayken Center for Addiction Medicine, which ...

Private clinics' peddling of unproven stem cell treatments is unsafe and unethical

July 7, 2017
Stem cell science is an area of medical research that continues to offer great promise. But as this week's paper in Science Translational Medicine highlights, a growing number of clinics around the globe, including in Australia, ...

Popular heartburn drugs linked to higher death risk

July 4, 2017
Popular heartburn drugs called proton pump inhibitors (PPIs) have been linked to a variety of health problems, including serious kidney damage, bone fractures and dementia. Now, a new study from Washington University School ...

Most reproductive-age women using opioids also use another substance

June 30, 2017
The majority of reproductive-age and pregnant women who use opioids for non-medical purposes also use at least one other substance, ranging from nicotine or alcohol to cocaine, according to a University of Pittsburgh Graduate ...

At-risk chronic pain patients taper opioids successfully with psychological tools

June 28, 2017
Psychological support and new coping skills are helping patients at high risk of developing chronic pain and long-term, high-dose opioid use taper their opioids and rebuild their lives with activities that are meaningful ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.